DAY ONE 1st November
NEWSLETTER Technology platforms mind the gap CordenPharma’s recent investments and global platform approach to CDMO development and commercialisation support pharma innovators to address their drug lifecycle gaps and reach patients faster.
A
cross the spectrum of drug development, CDMO CordenPharma is aligning its facilities and technology platforms to mind the gaps pharma and biotech innovators often encounter as they work through development phases towards commercial markets and patients. Designed to promote the rapid scale-up of preclinical, clinical and commercial manufacturing capabilities, CordenPharma offers fresh thinking by experts in the forefront of their field and the latest science to accelerate development of today’s most advanced large and smallmolecule therapeutics.
With a fully-integrated supply model as an overarching focus, CordenPharma has made recent, significant investments under all five technology platforms (Highly Potent and Oncology – Lipids and Carbohydrates – Peptides – Injectables – Small Molecules) in its current Good Manufacturing Practice (cGMP) facility network across Europe and the USA to create the stable, streamlined outsourcing pharma needs to develop and commercialise critical medications, and reach global patients successfully. To read more go to: https://www. lskh.digital/article/technologyplatforms-mind-the-gap/
Farmabios, Novasep and PharmaZell are now Axplora c Following the merger of Novasep and PharmaZell Group in April 2022, the Farmabios, Novasep and PharmaZell brands are now being unified under a single name. c The merger brings together companies that share a track record of high quality, reliability and a complementary set of differentiated technologies. c The name Axplora reflects the ambition to be the partner of choice for complex APIs. It conveys the Axplora spirit and agility, underpinned by an innovative mindset which drives the company and its employees.
Farmabios, Novasep and PharmaZell officially announced today that they are coming together under the new brand Axplora. This announcement comes just 6 months after the closure of the merger of the Novasep and the PharmaZell Group. This marks the last step in the creation of Axplora, a leading Active Pharmaceutical Ingredients (API) manufacturing partner for pharmaceutical
and biotechnology companies worldwide, with a long track record of reliably developing and scaling up complex production processes and delivering medicines on time and at scale, to the highest industry standards. To read more go to: https://www. lskh.digital/news/farmabiosnovasep-and-pharmazell-are-nowaxplora/
Quotient Sciences completes major expansion of drug substance manufacturing facility Quotient Sciences, the drug development and manufacturing accelerator, has completed the expansion of its drug substance manufacturing facility in Alnwick, UK. The £6 million project results in a state-of-the-art drug substance manufacturing capability that can deliver integrated support for customers from candidate
selection through to early clinical development and beyond. The expansion delivers multipurpose capacity of up to 15 GMP reactor streams with reactor volumes ranging from 5 liters up to 150 liters and tactical deployment of batch or continuous flow chemistry technologies to optimize drug substance manufacturing
CKH.DIGITAL
c
processes. The facility has been designed adopting Industry 4.0 principles, with the inclusion of a predictive process control system (PharmaMV) improving the transfer from small-scale process research and development (PR&D) into manufacture of multi-kilogram quantities of drug substance for clinical use.
Mark Egerton CEO To read more go to: https:// www.lskh.digital/news/quotientsciences-completes-majorexpansion-of-drug-substancemanufacturing-facility/
LSKH.DIGITAL